Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VidPrevtyn Beta versus Comirnaty BA.4-5 booster immunogenicity study in previously mRNA-vaccinated adults
2022-002715-38Phase 4Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2023
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4 trial of monovalent [B.1.351] CoV2 preS dTM-AS03 and Comirnaty Bivalent Original/Omicron BA.4/BA.5 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoints: Coprimary immunogenicity endpoint and Reactogenicity. Started Feb 2023; status: completed.
02
Drugs
monovalent [B.1.351] CoV2 preS dTM-AS03Comirnaty Bivalent Original/Omicron BA.4/BA.5
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2022-002715-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002715-38.